Argos Therapeutics (ARGS) Reports Q3 Loss of $0.10/Share

Argos Therapeutics (NASDAQ: ARGS) reported Q3 EPS of ($0.10), versus ($0.32) reported last year. Revenue for the quarter came in at $53.5 thousand, versus $146.76 thousand reported last year.

For earnings history and earnings-related data on Argos Therapeutics (ARGS) click here.

You May Also Be Interested In

• Is Treasury selloff a major issue for stock market bulls?
• INVO Fertility (IVF) Tops Q2 EPS by 105c
• Yum! Brands (YUM) PT Lowered to $180 at Argus